UPD in hematologic disorders
| Disease . | References . | Array . | Frequency, % . | Notes . |
|---|---|---|---|---|
| AML | 47 | 250K | 81 | Secondary, includes MPN |
| 46 | 250K | 23 | Secondary | |
| 69 | 10K | 17 | Primary, UPD13q limited to intermediate-risk group, all UPD lost on remission | |
| 6 | 10K | 12 | Primary, lost on remission | |
| 41 | 10K | 22.7 | All normal karyotype | |
| 70 | 10K | 11; 48 | At diagnosis; at relapse | |
| 49 | 250K | 34 | Secondary | |
| ALL | 5 | 10K | 40; 80 | At diagnosis; at relapse |
| 3 | 500K | 32.5 | ||
| 2 | 100K; 500K | 21 | ||
| 71 | 50K; 250K | 24 | ||
| 72 | 250K | 21; 36 | At diagnosis; at relapse | |
| MM | 68 | 50K | 10 | |
| CLL | 73 | 50K | 7 | Untreated |
| 67 | 10K; 50K | 20 | ||
| MDS | 54 | 250K | 8 | All telomeric, > 21 Mb |
| 66 | 50K | 33 | Low-risk MDS | |
| 46 | 250K | 20 | ||
| 31 | 10K; 50K; 250K | 46 | Low-risk MDS | |
| 74 | 250K | 12 | Normal karyotype by MC | |
| 75 | 500K | 62 | CD34+, all small (< 5 Mb) | |
| 49 | 250K | 18 | ||
| 76 | 50K | 33 | ||
| MDS/MPN | 46 | 250K | 35 | Most prevalent in CMML |
| 47 | 250K | 36; 11 | MDS/MPNu; RARSt | |
| 49 | 250K | 44 | MDS/MPNu, CMML, sAML | |
| 54 | 6.0 | 19 | JMML, UPD11q | |
| 57 | 250K | 8 | JMML, UPD11q | |
| 61 | 100K | 80; 0 | JMML with NF1 mutation; without NF1 mutation | |
| 52 | 250K | 28 | RARSt |
| Disease . | References . | Array . | Frequency, % . | Notes . |
|---|---|---|---|---|
| AML | 47 | 250K | 81 | Secondary, includes MPN |
| 46 | 250K | 23 | Secondary | |
| 69 | 10K | 17 | Primary, UPD13q limited to intermediate-risk group, all UPD lost on remission | |
| 6 | 10K | 12 | Primary, lost on remission | |
| 41 | 10K | 22.7 | All normal karyotype | |
| 70 | 10K | 11; 48 | At diagnosis; at relapse | |
| 49 | 250K | 34 | Secondary | |
| ALL | 5 | 10K | 40; 80 | At diagnosis; at relapse |
| 3 | 500K | 32.5 | ||
| 2 | 100K; 500K | 21 | ||
| 71 | 50K; 250K | 24 | ||
| 72 | 250K | 21; 36 | At diagnosis; at relapse | |
| MM | 68 | 50K | 10 | |
| CLL | 73 | 50K | 7 | Untreated |
| 67 | 10K; 50K | 20 | ||
| MDS | 54 | 250K | 8 | All telomeric, > 21 Mb |
| 66 | 50K | 33 | Low-risk MDS | |
| 46 | 250K | 20 | ||
| 31 | 10K; 50K; 250K | 46 | Low-risk MDS | |
| 74 | 250K | 12 | Normal karyotype by MC | |
| 75 | 500K | 62 | CD34+, all small (< 5 Mb) | |
| 49 | 250K | 18 | ||
| 76 | 50K | 33 | ||
| MDS/MPN | 46 | 250K | 35 | Most prevalent in CMML |
| 47 | 250K | 36; 11 | MDS/MPNu; RARSt | |
| 49 | 250K | 44 | MDS/MPNu, CMML, sAML | |
| 54 | 6.0 | 19 | JMML, UPD11q | |
| 57 | 250K | 8 | JMML, UPD11q | |
| 61 | 100K | 80; 0 | JMML with NF1 mutation; without NF1 mutation | |
| 52 | 250K | 28 | RARSt |
MM indicates multiple myeloma; MDS/MPNu, MDS/MPN unclassifiable; RARSt, refractory anemia with ring sideroblasts in transformation; sAML, secondary AML; and JMML, juvenile myelomonocytic leukemia.